Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (404)	8/31/1999 11:20:00 AM
From: Larry Liebman	Read Replies (1) \| Respond to of 1475

AMGN has 500 million/sh outstanding, market cap $40 billion+. BTRN has 9 million/sh outstanding, market cap $50 million. One point increase in AMGN= 10x market cap of BTRN. Added some BTRN today at 5 1/2. Surprised AMGN has not made use of its cap to digest smaller biotech brethren.

To: scaram(o)uche who wrote (404)	9/7/1999 11:12:00 AM
From: Bluegreen	Respond to of 1475

Dr. Harmon, you stated >>>>>>>>The answer to your question is that some inventions are best protected by trade secret.<<<<< Ah, but isn't there a difference between trade secrets and DEVELOPED TREATMENTS? BTW, we are starting to get some writeups in Prohost but nothing you haven't already covered, it seems.

To: scaram(o)uche who wrote (404)	9/8/1999 1:42:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1475

thanks, PB....... hematology.org Scientific Subcommittee on Transplantation Biology Induction of Mixed Chimerism by Allogeneic Hematopoietic Cell Transplantation Chair: Karl G. Blume, M.D., Stanford University, Palo Alto, CA Speakers: Karl G. Blume, M.D., Stanford University, Palo Alto,, CA Introduction: Mixed Chimerism Samuel Strober, M.D., Stanford University, Palo Alto, CA Which T Cells Are Needed for Engraftment and Graft-Versus-Tumor Effect? Megan Sykes, M.D., Harvard Medical School, Boston, MA From Murine Models of Chimerism to Clinical Transplantation Rainer F. Storb, M.D., Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA Mixed Chimerism and Graft-Versus-Tumor Effect - A Curative Concept Derived from the Dog Model